Binding of the NG2 Proteoglycan to Kringle Domains Modulates the Functional Properties of Angiostatin and Plasmin(ogen)*
暂无分享,去创建一个
[1] T. L. Moser,et al. The extracellular matrix proteins laminin and fibronectin contain binding domains for human plasminogen and tissue plasminogen activator. , 1993, The Journal of biological chemistry.
[2] K. Hirschi,et al. PDGF, TGF-β, and Heterotypic Cell–Cell Interactions Mediate Endothelial Cell–induced Recruitment of 10T1/2 Cells and Their Differentiation to a Smooth Muscle Fate , 1998, The Journal of cell biology.
[3] J. Folkman. Clinical Applications of Research on Angiogenesis , 1995 .
[4] W. Stallcup,et al. Interaction of the NG2 proteoglycan with the actin cytoskeleton , 1996, Journal of cellular biochemistry.
[5] Lars Holmgren,et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.
[6] P. Dell’Era,et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[7] A. Nishiyama,et al. Expression of NG2 proteoglycan causes retention of type VI collagen on the cell surface. , 1993, Molecular biology of the cell.
[8] H. Chapman,et al. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. , 1997, Current opinion in cell biology.
[9] W. Stallcup,et al. Interaction of the NG2 chondroitin sulfate proteoglycan with type VI collagen , 1990, The Journal of cell biology.
[10] T Ochiya,et al. PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. , 1999, Journal of cell science.
[11] M. Kramer,et al. Generation of cell surface-bound plasmin by cell-associated urokinase-type or secreted tissue-type plasminogen activator: a key event in melanoma cell invasiveness in vitro. , 1992, Experimental cell research.
[12] D. Sims,et al. The pericyte--a review. , 1986, Tissue & cell.
[13] K. Hirschi,et al. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. , 1999, Circulation research.
[14] P. Lerch,et al. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. , 1980, European journal of biochemistry.
[15] D. Rifkin,et al. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self- regulating system , 1990, The Journal of cell biology.
[16] C. Heldin,et al. Co‐localization of NG2 proteoglycan and PDGF α‐receptor on O2A progenitor cells in the developing rat brain , 1996, Journal of neuroscience research.
[17] T. L. Moser,et al. Binding of human plasminogen to basement-membrane (type IV) collagen. , 1992, The Biochemical journal.
[18] P. D’Amore,et al. Heparin and Growth Control of Vascular Cells a , 1989, Annals of the New York Academy of Sciences.
[19] D. Rifkin,et al. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor-beta 1-like molecule by plasmin during co-culture , 1989, The Journal of cell biology.
[20] J. Félez. Plasminogen binding to cell surfaces , 1998 .
[21] K. Danø,et al. Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.
[22] S. Strickland,et al. Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and parietal endoderm , 1976, Cell.
[23] W. Stallcup,et al. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. , 1995, Experimental cell research.
[24] H. Kobayashi,et al. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. , 1994, Cancer research.
[25] J. Folkman,et al. Fighting cancer by attacking its blood supply. , 1996, Scientific American.
[26] M. Llinás,et al. Ligand specificity of human plasminogen kringle 4. , 1991, Biochemistry.
[27] W. Risau,et al. Mechanisms of angiogenesis , 1997, Nature.
[28] R. Highsmith. Isolation and properties of a plasminogen activator derived from canine vascular tissue. , 1981, The Journal of biological chemistry.
[29] I. Herman,et al. Pericyte growth and contractile phenotype: Modulation by endothelial‐synthesized matrix and comparison with aortic smooth muscle , 1993, Journal of cellular physiology.
[30] N. Bouck,et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. , 1998, Blood.
[31] B. Wiman,et al. Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. , 1975, European journal of biochemistry.
[32] S Ferrone,et al. Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. , 1989, The American journal of pathology.
[33] A. Nishiyama,et al. Generation of truncated forms of the NG2 proteoglycan by cell surface proteolysis. , 1995, Molecular biology of the cell.
[34] D. Marti,et al. Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω‐aminocarboxylic acids , 1994 .
[35] D. Rifkin. Cross-talk among proteases and matrix in the control of growth factor action* , 1997 .
[36] J. Folkman,et al. Kringle Domains of Human Angiostatin , 1996, The Journal of Biological Chemistry.
[37] D. Rifkin,et al. Biology and biochemistry of proteinases in tumor invasion. , 1993, Physiological reviews.
[38] W. Stallcup,et al. High-affinity Binding of Basic Fibroblast Growth Factor and Platelet-derived Growth Factor-AA to the Core Protein of the NG2 Proteoglycan* , 1999, The Journal of Biological Chemistry.
[39] K. Larsson,et al. Molecular cloning and characterization of a full‐length cDNA clone for human plasminogen , 1987, FEBS letters.
[40] W. Stallcup,et al. Expression of the NG2 proteoglycan enhances the growth and metastatic properties of melanoma cells , 1998, Journal of cellular physiology.
[41] L. Lim,et al. Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas , 1999, Nature Cell Biology.
[42] M. Schrappe,et al. Correlation of chondroitin sulfate proteoglycan expression on proliferating brain capillary endothelial cells with the malignant phenotype of astroglial cells. , 1991, Cancer research.
[43] W. Stallcup,et al. NG2 proteoglycan and the actin-binding protein fascin define separate populations of actin-containing filopodia and lamellipodia during cell spreading and migration. , 1996, Molecular biology of the cell.
[44] D. Sane,et al. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration In vitro. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[45] M. O. Dayhoff,et al. Atlas of protein sequence and structure , 1965 .
[46] E. Pasquale,et al. The multi‐PDZ domain protein MUPP1 is a cytoplasmic ligand for the membrane‐spanning proteoglycan NG2 , 2000, Journal of cellular biochemistry.
[47] P. Wesseling,et al. Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme: An Immuno‐light and Immuno‐electron Microscopic Study , 1995, Journal of neuropathology and experimental neurology.
[48] F. Ruggiero,et al. The Membrane-spanning Proteoglycan NG2 Binds to Collagens V and VI through the Central Nonglobular Domain of Its Core Protein* , 1997, The Journal of Biological Chemistry.
[49] K. Constantine,et al. Ligand interactions with the kringle 5 domain of plasminogen. A study by 1H NMR spectroscopy. , 1990, The Journal of biological chemistry.
[50] D. Barritt,et al. Cytoskeletal reorganization induced by engagement of the NG2 proteoglycan leads to cell spreading and migration. , 1999, Molecular biology of the cell.
[51] P A D'Amore,et al. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells , 1987, The Journal of cell biology.
[52] D. Belin,et al. The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.
[53] K. Danø,et al. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.
[54] A. Nishiyama,et al. A central segment of the NG2 proteoglycan is critical for the ability of glioma cells to bind and migrate toward type VI collagen. , 1997, Experimental cell research.
[55] P. Lindahl,et al. Not all myofibroblasts are alike: revisiting the role of PDGF‐A and PDGF‐B using PDGF‐targeted mice , 1998, Current opinion in nephrology and hypertension.
[56] R. Timpl,et al. Binding of the NG2 Proteoglycan to Type VI Collagen and Other Extracellular Matrix Molecules* , 1996, The Journal of Biological Chemistry.
[57] J. Prince,et al. The primary structure of NG2, a novel membrane-spanning proteoglycan , 1991, The Journal of cell biology.
[58] Y. Lu,et al. The tumor-suppressing activity of angiostatin protein resides within kringles 1 to 3. , 1999, Biochemical and biophysical research communications.
[59] D. Walz,et al. Thrombospondin interaction with plasminogen. Evidence for binding to a specific region of the kringle structure of plasminogen , 1989 .
[60] M. Llinás,et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[61] A. Pearlman,et al. Chondroitin sulfate proteoglycans in the developing cerebral cortex: The distribution of neurocan distinguishes forming afferent and efferent axonal pathways , 1995, The Journal of comparative neurology.
[62] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[63] Itzhak D. Goldberg,et al. Regulation of Angiogenesis , 1996, Experientia Supplementum.
[64] J. Hoover-Plow,et al. The cell biology of the plasminogen system , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[65] S. Pizzo,et al. Regulation of plasminogen activation by components of the extracellular matrix. , 1990, Biochemistry.
[66] R. Silverstein,et al. Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. , 1985, The Journal of biological chemistry.
[67] R Pasqualini,et al. NG2 proteoglycan-binding peptides target tumor neovasculature. , 1999, Cancer research.
[68] J. Zeuthen,et al. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. , 1985, The Journal of biological chemistry.
[69] P. Wesseling,et al. AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS , 1996, The Journal of pathology.
[70] G. Markus. Conformational changes in plasminogen, their effect on activation, and the agents that modulate activation rates — a review , 1996 .